Jagsonpal Pharma's 47th AGM: Key Resolutions Passed Unanimously
Jagsonpal Pharmaceuticals Limited held its 47th AGM on September 18, 2026. All five resolutions, including financial statement adoption, dividend declaration, director reappointment, cost auditor remuneration ratification, and independent director appointment, were passed with strong majority. The results were confirmed by the Scrutinizer's Report.
The announcement pertains to routine corporate governance matters such as the approval of financial statements, dividend declaration, and director appointments, which are standard procedures and do not indicate significant changes in the company's operations or financial outlook.
The announcement details the successful passing of all resolutions at the company's AGM with overwhelming support, indicating positive shareholder engagement and approval of the company's proposals.
Jagsonpal Pharmaceuticals Limited has announced the voting results of its 47th Annual General Meeting (AGM), which was held on Friday, September 18, 2026, through Video Conferencing/Other Audio-Visual Means. The meeting commenced at 3:30 p.m. IST and concluded at 4:04 p.m. IST.
All five resolutions presented at the AGM were passed with the requisite majority. These included the adoption of the Audited Financial Statements for the Financial Year ended March 31, 2026, and the declaration of a dividend for the same financial year. Additionally, the reappointment of Mr. Prithipal Singh Kochhar as a director, the ratification of remuneration for M/s. Kirit Mehta & Co. LLP as Cost Auditors for the Financial Year ending March 31, 2027, and the appointment of Mr. Anil Kumar Matai as an Independent Director were approved.
The voting process, which included remote e-voting and e-voting during the AGM, saw overwhelming support for all resolutions, with most passing with close to 100% of the votes in favour. The Scrutinizer's Report, dated September 21, 2026, confirmed the results of the voting.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.